Explore more publications!
Wellness Today St. Kitts & Nevis
Got News to Share?

Wellness Today St. Kitts & Nevis: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Today St. Kitts & Nevis.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on September 17, 2025

Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
September 17, 2025

Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study

Indeterminate GlobeNewswire
Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering
September 17, 2025

Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering

Indeterminate GlobeNewswire
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
September 17, 2025

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Indeterminate GlobeNewswire
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe
September 17, 2025

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

Indeterminate GlobeNewswire
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
September 17, 2025

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

Indeterminate GlobeNewswire
Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
September 17, 2025

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

Indeterminate GlobeNewswire
Regional Health Properties, Inc. Completes Repurchases of 12.5% Series B Cumulative Redeemable Preferred Shares
September 17, 2025

Regional Health Properties, Inc. Completes Repurchases of 12.5% Series B Cumulative Redeemable Preferred Shares

Indeterminate GlobeNewswire
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
September 17, 2025

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Indeterminate GlobeNewswire
Joint Commission and Coalition for Health AI (CHAI) Release Initial Guidance to Support Responsible AI Adoption Across U.S. Health Systems
September 17, 2025

Joint Commission and Coalition for Health AI (CHAI) Release Initial Guidance to Support Responsible AI Adoption Across U.S. Health Systems

Indeterminate GlobeNewswire
Joint Commission Announces 2025 Quality and Patient Safety Award Winners
September 17, 2025

Joint Commission Announces 2025 Quality and Patient Safety Award Winners

Indeterminate GlobeNewswire
Global Patient Monitoring Devices Market to Cross USD 110 Billion Mark by 2032 | DelveInsight
September 17, 2025

Global Patient Monitoring Devices Market to Cross USD 110 Billion Mark by 2032 | DelveInsight

Indeterminate GlobeNewswire
The Association of American Physicians and Surgeons (AAPS) Supports HHS Secretary Kennedy and Making America Healthy Again (MAHA)
September 17, 2025

The Association of American Physicians and Surgeons (AAPS) Supports HHS Secretary Kennedy and Making America Healthy Again (MAHA)

Indeterminate GlobeNewswire
Thirty Inspiring Middle School Scientists and Engineers Shine as Finalists in the Thermo Fisher Scientific Junior Innovators Challenge
September 17, 2025

Thirty Inspiring Middle School Scientists and Engineers Shine as Finalists in the Thermo Fisher Scientific Junior Innovators Challenge

Indeterminate GlobeNewswire
FMOL Health Shows Drastic Reduction in Sepsis Related Deaths
September 17, 2025

FMOL Health Shows Drastic Reduction in Sepsis Related Deaths

Indeterminate GlobeNewswire
Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma’s Phase 3 Clinical Trial Results
September 17, 2025

Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma’s Phase 3 Clinical Trial Results

Indeterminate GlobeNewswire
Young Innovations Announces Distribution Partnership with OrthoNu® to Expand Its Specialty Orthodontic Care Product Offering
September 17, 2025

Young Innovations Announces Distribution Partnership with OrthoNu® to Expand Its Specialty Orthodontic Care Product Offering

Indeterminate GlobeNewswire
At CPHI Frankfurt, TekniPlex Healthcare to Present Full Range of Barrier Blister Films, Customized Liquid Drug Delivery Solutions and Live Demonstrations of Latest Filling-Sealing Machine
September 17, 2025

At CPHI Frankfurt, TekniPlex Healthcare to Present Full Range of Barrier Blister Films, Customized Liquid Drug Delivery Solutions and Live Demonstrations of Latest Filling-Sealing Machine

Indeterminate GlobeNewswire
Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection
September 17, 2025

Mapi Pharma Announces First Patient Recruited in Phase-I/II Study of Cariprazine Depot Once Monthly Injection

Indeterminate GlobeNewswire
Acentra Health Named one of the ‘Fastest Growing Companies’ by the Washington Business Journal
September 17, 2025

Acentra Health Named one of the ‘Fastest Growing Companies’ by the Washington Business Journal

Indeterminate GlobeNewswire
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
September 17, 2025

Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions